作者
Emily Feld, Joanna Harton, Neal J Meropol, Blythe JS Adamson, Aaron Cohen, Ravi B Parikh, Matthew D Galsky, Vivek Narayan, John Christodouleas, David J Vaughn, Rebecca A Hubbard, Ronac Mamtani
发表日期
2019/10/1
期刊
European urology
卷号
76
期号
4
页码范围
524-532
出版商
Elsevier
简介
Background
Limited data compare first-line carboplatin-based chemotherapy and immune checkpoint blockade in cisplatin-ineligible metastatic urothelial carcinoma (mUC) patients. The primary evidence guiding treatment decisions was a recent Food and Drug Administration/European Medicines Agency safety alert based on emerging data from two ongoing phase III trials, reporting shorter survival in programmed death-ligand 1 (PD-L1)-negative patients receiving immunotherapy. Final results from these trials are unknown.
Objective
To compare survival in cisplatin-ineligible mUC patients receiving first-line immunotherapy versus those receiving carboplatin-based chemotherapy.
Design, setting, and participants
We conducted a retrospective cohort study of 2017 mUC patients receiving first-line carboplatin-based chemotherapy (n = 1530) or immunotherapy (n = 487) from January 1, 2011 to May 18, 2018 …
学术搜索中的文章
E Feld, J Harton, NJ Meropol, BJS Adamson, A Cohen… - European urology, 2019